Table 2.
Key information on 10 genes and their disease associations, drug actions, clinical trials, and tractability predictions
| Gene | Global score | Known drugs | Phase | Tractability predictions | ||
|---|---|---|---|---|---|---|
| Small molecule clinical precedence |
Antibody clinical precedence |
Protac | ||||
| ESR2 | 0.485 | ESTRAMUSTINE | Phase III | 5 | 3 | 5 |
| PHOSPHATE | ||||||
| SODIUM | ||||||
| STAT3 | 0.355 | – | – | 3 | 1 | 4 |
| SOD2 | 0.014 | – | – | 1 | – | 3 |
| PPARA | 0.011 | – | – | 5 | – | 1 |
| MMP9 | 0.082 | – | – | 5 | 4 | 2 |
| AKT1 | 0.627 | IPATASERTIB | Phase III | 5 | 2 | 5 |
| CAPIVASERTIB | Phase III | |||||
| MK-2206 | Phase II | |||||
| AFURESERTIB | Phase I | |||||
| GSK3B | 0.259 | LITHIUM CARBONATE | Phase I | 5 | 2 | 4 |
| PIK3CA | 0.62 | BUPARLISIB | Phase II | 5 | 1 | 4 |
| SAMOTOLISIB | Phase II | |||||
| SONOLISIB | Phase II | |||||
| APITOLISIB | Phase I | |||||
| DACTOLISIB | Phase I | |||||
| COPANLISIB | Phase I | |||||
| ESR1 | 0.558 | TAMOXIFEN CITRATE | Phase III | 5 | 3 | 3 |
| FULVESTRAN | Phase II | |||||
| ESTETROL | Phase I | |||||
| MDM2 | 0.444 | – | – | 5 | 1 | 4 |